Immuno US 2024

28 - 29 October 2024 | San Diego, CA

Delivering advanced, commercially viable immunotherapies to meet unmet medical need

Explore Immuno US 2024: Facilitating the Next Generation of Advanced Immunotherapies

Join a like-minded community of over 400 scientists & business leaders committed to accelerating the development & approval of advanced immunotherapies to address unmet medical needs. 

Deep-dive into the most need-to-know data, technologies and strategies in drug discovery, clinical development & manufacturing across multiple modalities, from novel cell therapies and therapeutic antibodies, to oncolytic viruses and the microbiome. From the big-picture challenges in the regulation and commercialization of these novel products through to the technical considerations affecting each stage of the development pipeline, Immuno US highlights the tools you need to fast-track your product development. Alongside presentations and panel discussions, the conference features a host of formal and informal networking opportunities allowing you to foster long-term collaborations and meet the right partners for your research goals.

Immuno US 2024

  • Gain insights into emerging immune-targeting modalities with the potential to transform patient care, including cell & gene therapies, therapeutic antibodies, vaccines & oncolytic viruses
  • Take a deep dive into translational & pre-clinical development with discussions on animal modelling techniques and screening strategies to assess safety and efficacy
  • Ensure your late stage development is set up for success. Streamline your route through the clinic with the successful implementation of effective trial design strategies, and ensure scalability of your product 

Agenda at a Glance

  • Day One | Track 1: Discovery & Validation of Novel Modalities – Cell & Gene Therapy
  • Day One | Track 2: Discovery & Validation of Novel Modalities – Microbiome & the Gut-Immune Axis
  • Day One | Track 3: Biomarkers & Multi-Omics For Precision Oncology & Immunology
  • Day One | Track 4: Designing Clinical Trials for Success
  • Day Two | Track 1: Discovery & Validation of Novel Modalities – Therapeutic Antibodies
  • Day Two | Track 2: Discovery & Validation of Novel Modalities – Oncolytic Viruses & Cancer Vaccines
  • Day Two | Track 3: Predictive Models & Tools for Preclinical Evaluation
  • Day Two | Track 4: Manufacturing Novel Products at Scale

What to Expect


leading pharma, biotech & academic delegates

hours of presentations, discussions & interactive content
hours of networking breaks, including speed networking & refreshments
hours of pre-arranged 1-2-1 meetings, facilitating business growth
Interactive Presentations
Exhibition Hall
Networking Drinks
Poster Display
Event App Swapcard

Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of experiences

  • Engaging Thought Leadership

    Over 80 dynamic interactive discussions, roundtables, and presentations curated with insights from top industry leaders and experts
  • Global Technological Showcase

    An international exhibition showcasing cutting-edge technologies and services from leading providers in the scientific field.
  • Networking Emphasis

    Unparalleled networking opportunities, including speed networking sessions, a vibrant drinks reception, and informal gatherings to foster meaningful connections
  • Innovative Poster Displays

    Inspiring poster displays and presentations unveiling the latest breakthroughs from emerging biotech, pharma, and academic institutions

Key Themes for Immuno US 2024

The 2024 programme has been expertly designed to explore the key immune-targeting modalities transforming patient care - from cell & gene therapies, to therapeutic antibodies, to vaccines, viruses and the microbiome. Discussions will also revolve around the promising landscape of multi-omics technologies for immuno-oncology, diving into the utilisation of spatial biology and single cell technology in immunotherapy. As the immuno-oncology field continues to advance, prepare for clinical success and learn from key opinion leaders who are implementing effective clinical trial design strategies and leveraging the latest digital technologies to progress their candidates.

Companies Represented Include

Meet Our Expert Speakers

The event brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data, and industry outlooks. Below were some of the featured speakers at Immuno US 2023: 12 - 13 October 2023, San Diego, USA

Amy Rappaport
Senior Director,
Gritstone Oncology
Eric Smith
Executive Director,
Jean-Francois Martini
Executive Director, Translational Oncology Lead, Global Product Development,
Marya Chaney
Executive Director, Clinical Research,
Merck US
Peggy Thompson
Vice President Biology,
Thomas Schuerpf
Vice President, Head of Development,
Incendia Therapeutics

All Speakers

Aditya Murthy
Gilead Sciences
Alexis Combes
Assistant Professor and Director of Disease to Biology CoLab,
UC San Francisco
Angus Sinclair
Senior Vice President Immuno-oncology,
IGM Biosciences
Christine Bowman
Principal Investigator, Biology,
Arcus Biosciences
Courtney Beers
Chief Scientific Officer,
Tizona Therapeutics
Faith Griffin
Associate Director, Translational Biomarker and Bioanalysis,
Floyd Romesberg
Hyun Yong Jin
Principal Scientist,
I-Ming Wang
Kareem Azab
Associate Professor,
University of Texas Southwestern Medical Center
Keegan Cooke
Senior Scientist,
Kelly Loyet
Distinguished Scientist,
Marilena Gallotta
Principal Scientist, Preclinical Pharmacology,
Matthew Chun
Senior Principal Scientist,
Michael Abadier
Director, Translational Medicine - Oncology,
Moderna Therapeutics
Niels Vande Casteele
Founding President,
Nikos Kourtis
Principal Scientist,
Sailaja Battula
Vice-President, R&D,
Shigeki Miyake-Stoner
Head of Technology,
Replicate Bioscience
Shilpa Keerthivasan
Principal Scientist,
Bristol Myers Squibb
Sonia Feau
Director of Biology,
Onchilles Pharma Inc
Thierry Guillaudeux
Chief Scientific Officer,

Interested in Sponsoring?

Oxford Global’s range of sponsorship opportunities are highly effective in enabling market immersion and visibility, with direct access to clients and potential customers.

Learn more

Latest Resources

First Patient Dosed with NK Cell Therapy for the Treatment of an Autoimmune Disease, Lupus Nephritis

The NK cell therapy is being trialled in combination with monoclonal antibody therapy and hopes to induce B-cell depletion.

Positive Results from iNKT Cell Therapy Clinical Trial for COVID-19 ARDS

The small exploratory trial shows signs that iNKT cells can improve the survival rate of respiratory distress from COVID-19.

How to Improve Therapeutic Efficacy: Safety Considerations in Oncolytic Virotherapy

Oncolytic virotherapy targets cancer cells with viruses, promising personalized treatment with minimal side effects. Safety measures include minimizing off-target effects and systemic spread. Combining with immunotherapy enhances efficacy, revolutionizing cancer treatment.

Zika Virus Tested as an Effective Oncolytic Agent for Glioblastoma in In Vitro Models

More results are in for the oncolytic potential of the Zika virus, where it has proven effective against the most common form of brain cancer in vitro.

Post-Event Proceedings – Immuno 2023

Concise and insightful summaries of presentations delivered by prominent thought leaders at Immuno 2023.

In Vivo Models Show Survival Promise for Zika Oncolytic Viral Therapy for Neuroblastoma

One of the deadliest cancers in children could have its survival rate improved by the advent of new research into the oncolytic effect of Zika virus.

Plan Your Visit

Doubletree by Hilton San Diego Mission Valley
7450 Hazard Center Dr, San Diego, CA 92108

By Trolley

The closest Trolley stop to the hotel is Hazard Center Station – this stop is served by the Sycuan Green Line. The hotel is a 7 mins walk from the station. When alighting at this stop, walk north on Hazard Center East Driveway towards Hazard Center Drive. Then turn left and the hotel will be on your right.

By Car

There is self-parking available (garage parking) at the hotel for $34 (this may be subject to state local taxes). There is no valet parking at this venue. For further information please contact the hotel directly. For driving instructions and a map, please click here

By Air

San Diego International Airport – The DoubleTree by Hilton San Diego – Mission Valley is 7 miles from the International Airport. A single taxi ride to the hotel will cost approx. $40 and will take around 20 minutes. Transportation to/from the hotel is provided by Super Shuttle, Cloud 9, or other shuttle services for approx. $10-$15 per person. Please click here for more information on travelling to the hotel from the airport.

By Bus

The closest bus stop to the venue is Camino De La Reina & Mission Center Rd, which is a 13min walk away. When alighting at this stop, walk north on Mission Center Rd towards Camino De La Reina. Turn left onto Hazard Center Dr and then right on to Frazee Rd – the hotel should be on the right hand side. Please click here for more information on Trolley and bus services in the area.

Oxford Global has secured a number of bedrooms at the Doubletree by Hilton San Diego Mission Valley at a reduced conference rate: 


  • Sunday 27th October 2024 – $265 (includes room rate, taxes & daily continental breakfast)


  • Monday 28th October 2024 – $265 (includes room rate, taxes & daily continental breakfast)


Should you wish to book a room, please click here.


The final cut-off date to book bedrooms is Friday 27th September 2024 – any bookings after this date are subject to availability and rates - any cancellations after 4th October are subject to full cancellation charges.


Additionally, we kindly remind all attendees to only book their accommodation if they are registered for the event. This ensures that accommodations are available for those who have officially secured their attendance.

We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.

As we continue to move forward with hosting our events in-person in 2024, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.

Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.

Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.

If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Advances in Immuno-Oncology US 2024 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.

Register Your Interest

Submit your details and a member of our team will be in touch